Citations

Showing 10 of 108162 citations.

Diagnostic and procedural intraoperative ultrasound: technique, tips and tricks for optimizing results
Lubner, Meghan G. , Gettle, Lori Mankowski , Dahiya, Nirvikar , Pickhardt, Perry J. , Kim, David H. , Ziemlewicz, Timothy J.

Mayo Clinic

The British Journal of Radiology | March 8, 2021 | Volume: 94 | Issue: 1121 | Pages: No page available

10.1259/bjr.20201406 | PMID 33684305 Get It

Intraoperative ultrasound (IOUS) is a valuable adjunctive tool that can provide real-time diagnostic information in surgery that has the potential to alter patient management and decrease complications. Lesion localization, characterization and staging can be performed, as well as surveying for additional lesions and metastatic disease. IOUS is commonly used in the liver for hepatic metastatic disease and hepatocellular carcinoma, in the pancreas for neuroendocrine tumors, and in the kidney for renal cell carcinoma. IOUS allows real-time evaluation of vascular patency and perfusion in organ transplantation and allows for early intervention for anastomotic complications. It can also be used to guide intraoperative procedures such as biopsy, fiducial placement, radiation, or ablation. A variety of adjuncts including microbubble contrast and elastography may provide additional information at IOUS. It is important for the radiologist to be familiar with the available equipment, common clinical indications, technique, relevant anatomy and intraoperative imaging appearance to optimize performance of this valuable imaging modality.
Feasibility Study of Vascularized Composite Urinary Bladder Allograft Transplantation in a Cadaver Model
Gargollo, Patricio C. , Prieto, Mikel , Butaney, Mohit , Cramer, Carl H. , Joshi, Vidhu B. , Granberg, Candace F. , Joshi, Vidhu, Ahmed, Mohamed E. , Heimbach, Julie K.

Mayo Clinic

Journal of Urology | March 8, 2021 | Volume: 206 | Issue: 1 | Pages: 115-123

10.1097/ju.0000000000001699 | PMID 33683936 Get It

Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits
Zand, Ladan , Leung, Nelson , Sethi, Sanjeev , Ters, Mireille El , Fervenza, Fernando C. , Leung, Nelson , Sethi, Sanjeev , El Ters, Mireille, Fervenza, Fernando C , Rajkumar, S. Vincent

Mayo Clinic

Journal of the American Society of Nephrology | March 8, 2021 | Volume: 32 | Issue: 5 | Pages: 1163-1173

10.1681/asn.2020101541 | PMID 33685975 Get It

Significance Statement Treatment of proliferative GN with monoclonal Ig deposition (PGNMID), in which direct deposition of the monoclonal proteins damages the kidney, is not established. Daratumumab, a monoclonal anti-CD38 antibody, has shown effectiveness as multiple myeloma therapy. In an open-label, phase 2 study, the authors evaluated safety and efficacy of a 6-month course of intravenous daratumumab in 11 patients with PGNMID and one with C3 glomerulopathy with monoclonal gammopathy. Five episodes of serious adverse events (two of which were infection related) occurred. All ten patients with PGNMID who received at least one daratumumab dose experienced a significant reduction in proteinuria at 6 months, which was sustained in seven patients by 12 months. Overall, in this pilot study, daratumumab’s acceptable toxicity profile and significant improvement in proteinuria, while stabilizing kidney function, suggest further investigation is warranted. Background Treatment of proliferative GN with monoclonal Ig deposits (PGNMID) is not established. A monoclonal anti-CD38 antibody (daratumumab) is effective in treating multiple myeloma. Abnormal plasma cell clones may play a role in the pathogenesis of PGNMID. Methods We evaluated daratumumab’s safety and efficacy in an open-label, phase 2 trial in 11 adults with PGNMID and one with C3 glomerulopathy (C3G) with monoclonal gammopathy. Patients had an eGFR >20 ml/min per 1.73 m 2 and proteinuria >1 g/d. They received daratumumab intravenously (16 mg/kg) once weekly for 8 weeks, and then every other week for eight additional doses. Primary outcome was safety, defined as major infections, grade 3 or 4 anemia, leukopenia, or thrombocytopenia. Secondary outcomes were rate of complete remission (proteinuria <500 mg/d with <15% decline in baseline eGFR) or partial remission (>50% reduction in 24-hour proteinuria with <30% decline in eGFR) and proteinuria at 6 and 12 months. Results One patient with C3G had GN unrelated to the monoclonal gammopathy, and one with PGNMID did not complete the first infusion. Five serious adverse events occurred. During the 12 months of the trial, six of the ten patients with PGNMID who received at least one dose of daratumumab had a partial response, and four had a complete response (an overall response rate of 100%). Three patients experienced relapse, two of whom re-entered partial remission after resuming daratumumab therapy. Proteinuria declined significantly, from a median of 4346 mg/d to 1264 mg/d by 12 months. Conclusions Daratumumab demonstrated an acceptable safety profile and resulted in significant improvement in proteinuria while stabilizing kidney function in patients with PGNMID, suggesting the drug merits further investigation. Clinical Trial registry name and registration number: Daratumumab in Treatment of PGNMID and C3 GN, NCT03095118
Declining Accuracy of the Traditional Diamond-Forrester Estimates of Pretest Probability of Coronary Artery Disease
Gibbons, Raymond J. , Miller, Todd D.

Mayo Clinic

JAMA Internal Medicine | March 8, 2021 | Volume: 181 | Issue: 5 | Pages: 579

10.1001/jamainternmed.2021.0171 | PMID 33683301 Get It

BRCA1 /2 and Endometrial Cancer Risk: Implications for Management
Foulkes, William D. , Foulkes, William D , Sherman, Mark E.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 8, 2021 | Volume: 113 | Issue: 9 | Pages: 1127-1128

10.1093/jnci/djab037 | PMID 33710310 Get It

The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19
Pirofski, Liise‐anne , Joyner, Michael J. , Casadevall, Arturo , Joyner, Michael J , Casadevall, Arturo

Mayo Clinic

mBio | March 8, 2021 | Volume: 12 | Issue: 2 | Pages: No page available

10.1128/mbio.03372-20 | PMID 33653885 Get It

Antibody therapies such as convalescent plasma and monoclonal antibodies have emerged as major potential therapeutics for coronavirus disease 2019 (COVID-19). Immunoglobulins differ from conventional antimicrobial agents in that they mediate direct and indirect antimicrobial effects that work in concert with other components of the immune system.
EBV-Positive Plasmacytomas Involving a Nasopharyngeal Angiofibroma in an Adolescent
Mariani, R , King, Rebecca L. , Liu, Huifei , Mariani, Rachel

Mayo Clinic

Pediatric and Developmental Pathology | March 8, 2021 | Volume: 24 | Issue: 3 | Pages: 264-268

10.1177/1093526621999022 | PMID 33683983 Get It

We report comprehensive characterization of an unusual collision tumor comprising extramedullary plasmacytomas and nasopharyngeal angiofibroma in a pediatric patient, which has yet to be reported. Histologically, the nasopharyngeal angiofibroma showed typical morphology with a diffuse, dense plasmacytic infiltrate in the stroma. The neoplastic plasma cells showed a spectrum of well-differentiated, plasmablastic, and anaplastic morphology, Epstein-Barr virus encoded RNA (EBER) positivity, and aberrant immunophenotype. Fluorescence in situ hybridization using a plasma cell myeloma targeted panel detected gains of 1q21.3 ( CKS1B, x3), 3q27 ( BCL6, x4), and 11q22.3 ( ATM, x3), but no rearrangement of ALK and MYC. A 50-gene next generation sequencing lymphoma panel failed to detect any pathogenic mutation. Plasmacytoma with EBER positivity and plasmablastic morphology must be distinguished from plasmablastic lymphoma due to different clinical management and prognosis. This case highlights the importance of a thorough pathological evaluation of a mass lesion with synchronous neoplastic processes.
Updating an Empirically Based Tool for Analyzing Congenital Heart Surgery Mortality
Jacobs, Marshall L., Jacobs, Jeffrey P. , Thibault, Dylan, Hill, Kevin D. , Anderson, Brett R. , Karamlou, Tara , Kumar, S. Ram , Mayer, John E. , Mery, Carlos M. , Nathan, Meena , Overman, David M. , Pasquali, Sara K. , Shahian, David M. , O’Brien, Sean M. , Kumar, S Ram , Jacobs, Jeffery P , Eghtesady, Pirooz , Louis, James D. St.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | March 8, 2021 | Volume: 12 | Issue: 2 | Pages: 246-281

10.1177/2150135121991528 | PMID 33683997 Get It

Objectives: STAT Mortality Categories (developed 2009) stratify congenital heart surgery procedures into groups of increasing mortality risk to characterize case mix of congenital heart surgery providers. This update of the STAT Mortality Score and Categories is empirically based for all procedures and reflects contemporary outcomes. Methods: Cardiovascular surgical operations in the Society of Thoracic Surgeons Congenital Heart Surgery Database (January 1, 2010 – June 30, 2017) were analyzed. In this STAT 2020 Update of the STAT Mortality Score and Categories, the risk associated with a specific combination of procedures was estimated under the assumption that risk is determined by the highest risk individual component procedure. Operations composed of multiple component procedures were eligible for unique STAT Scores when the statistically estimated mortality risk differed from that of the highest risk component procedure. Bayesian modeling accounted for small denominators. Risk estimates were rescaled to STAT 2020 Scores between 0.1 and 5.0. STAT 2020 Category assignment was designed to minimize within-category variation and maximize between-category variation. Results: Among 161,351 operations at 110 centers (19,090 distinct procedure combinations), 235 types of single or multiple component operations received unique STAT 2020 Scores. Assignment to Categories resulted in the following distribution: STAT 2020 Category 1 includes 59 procedure codes with model-based estimated mortality 0.2% to 1.3%; Category 2 includes 73 procedure codes with mortality estimates 1.4% to 2.9%; Category 3 includes 46 procedure codes with mortality estimates 3.0% to 6.8%; Category 4 includes 37 procedure codes with mortality estimates 6.9% to 13.0%; and Category 5 includes 17 procedure codes with mortality estimates 13.5% to 38.7%. The number of procedure codes with empirically derived Scores has grown by 58% (235 in STAT 2020 vs 148 in STAT 2009). Of the 148 procedure codes with empirically derived Scores in 2009, approximately one-half have changed STAT Category relative to 2009 metrics. The New STAT 2020 Scores and Categories demonstrated good discrimination for predicting mortality in an independent validation sample (July 1, 2017-June 30, 2019; sample size 46,933 operations at 108 centers) with C-statistic = 0.791 for STAT 2020 Score and 0.779 for STAT 2020 Category. Conclusions: The updated STAT metrics reflect contemporary practice and outcomes. New empirically based STAT 2020 Scores and Category designations are assigned to a larger set of procedure codes, while accounting for risk associated with multiple component operations. Updating STAT metrics based on contemporary outcomes facilitates accurate assessment of case mix.
Change in Posterior Tibial Slope in Skeletally Immature Patients With Anterior Cruciate Ligament Injury: A Case Series With a Mean 9 Years’ Follow-up
Martin, R. Kyle , Ekås, Guri Ranum , Benth, Jūratė Šaltytė , Kennedy, Nicholas I. , Krych, Aaron J. , Kennedy, Nicholas, Krych, Aaron J , Moatshe, Gilbert , Engebretsen, Lars

Mayo Clinic

The American Journal of Sports Medicine | March 8, 2021 | Volume: 49 | Issue: 5 | Pages: 1244-1250

10.1177/0363546521997097 | PMID 33683924 Get It

Background: Increased lateral posterior tibial slope (LPTS) is associated with increased rates of anterior cruciate ligament (ACL) injury and failure of ACL reconstruction. It is unknown if ACL deficiency influences the developing proximal tibial physis and slope in skeletally immature patients through anterior tibial subluxation and abnormal force transmission. Purpose: To assess the natural history of LPTS in skeletally immature patients with an ACL-injured knee. Study Design: Case series; Level of evidence, 4. Methods: A total of 38 participants from a previous study on nonoperative management of ACL injury in skeletally immature patients were included. During the initial study, bilateral knee magnetic resonance imaging (MRI) was performed within 1 year of enrollment and again at final follow-up. All patients were younger than 13 years at the time of enrollment, and final follow-up occurred a mean 10 years after the injury. MRI scans were retrospectively reviewed by 2 reviewers to determine bilateral LPTS for each patient and each time point. Linear mixed models were used to assess LPTS differences between knees, change over time, and association with operational status. Subgroup analyses were performed for patients who remained nonoperated throughout the study. Results: A total of 22 patients had ACL reconstruction before final follow-up and 16 remained nonoperated. In the entire study population, the mean LPTS was higher in the injured knee than in the contralateral knee at final follow-up by 2.0° ( P < .001; 95% CI, 1.3°–2.6°). The mean LPTS increased significantly in the injured knee by 0.9° ( P = .042; 95% CI, 0.03°–1.7°), while the mean LPTS decreased in the contralateral knee by 0.4° ( P = .363; 95% CI, –0.8° to 0.4°). A significant difference in LPTS was also observed in the nonoperated subgroup. No significant association was observed between LPTS and operational status. Conclusion: Lateral posterior tibial slope increased more in the ACL-injured knee than in the contralateral uninjured knee in a group of skeletally immature patients. Lateral posterior tibial slope at baseline was not associated with the need for surgical reconstruction over the study period.
Young at Gut—Turning Back the Clock with the Gut Microbiome
Narasimhan, Harish , Ren, Clarissa C. , Deshpande, Sharvari, Sylvia, Kristyn E.

Mayo Clinic

Microorganisms | March 8, 2021 | Volume: 9 | Issue: 3 | Pages: 555

10.3390/microorganisms9030555 | PMID 33800340 Get It

Over the past century, we have witnessed an increase in life-expectancy due to public health measures; however, we have also seen an increase in susceptibility to chronic disease and frailty. Microbiome dysfunction may be linked to many of the conditions that increase in prevalence with age, including type 2 diabetes, cardiovascular disease, Alzheimer’s disease, and cancer, suggesting the need for further research on these connections. Moreover, because both non-modifiable (e.g., age, sex, genetics) and environmental (e.g., diet, infection) factors can influence the microbiome, there are vast opportunities for the use of interventions related to the microbiome to promote lifespan and healthspan in aging populations. To understand the mechanisms mediating many of the interventions discussed in this review, we also provide an overview of the gut microbiome’s relationships with the immune system, aging, and the brain. Importantly, we explore how inflammageing (low-grade chronic inflammation that often develops with age), systemic inflammation, and senescent cells may arise from and relate to the gut microbiome. Furthermore, we explore in detail the complex gut–brain axis and the evidence surrounding how gut dysbiosis may be implicated in several age-associated neurodegenerative diseases. We also examine current research on potential interventions for healthspan and lifespan as they relate to the changes taking place in the microbiome during aging; and we begin to explore how the reduction in senescent cells and senescence-associated secretory phenotype (SASP) interplay with the microbiome during the aging process and highlight avenues for further research in this area.